Synthego Appoints CRISPR Pioneer Dr. Jennifer Doudna to Advisory Board to Accelerate Company’s Genome Engineering Mission

Redwood City, California – March 28, 2018 – Synthego, a leading provider of genome engineering solutions, today announced that genomic industry pioneer Dr. Jennifer Doudna has joined the company’s advisory board. Doudna, best known for co-inventing CRISPR, will advise Synthego on a variety of product, partnership, and business strategy initiatives to help amplify the company’s fast-growing impact in the genome engineering space.

First proposed as a gene editing tool by Doudna and her team in 2012, CRISPR now serves as the foundation for modern genome engineering and is considered one of the most exciting scientific advancements in history. Using CRISPR, researchers can precisely edit DNA to eradicate diseases and solve some of society’s biggest challenges. As one of the industry’s leading innovators, Doudna will bring her expertise and strategic counsel to Synthego’s board as the company accelerates the adoption of CRISPR by increasing access to the technology and standardizing its application across multiple areas of the life sciences, such as biopharma.

"Synthego is one of the most promising and necessary companies to emerge in the field of genome engineering," said Jennifer Doudna. "By increasing access to this scientific advancement, Synthego will have an immediate impact on life sciences researchers and is poised to transform the industry by making the application of CRISPR simpler, faster, and more valuable to innovators previously unable to realize its full potential."

The efficiency and agility of Synthego’s technology has positioned the company as one of the world’s leading authorities on CRISPR. Synthego’s full-stack genome engineering platform expedites research processes and allows scientists to study the fundamentals of biology, develop novel therapeutics for human disease, advance agriculture, and produce sustainable energy and chemicals. Most importantly, Synthego’s CRISPR offering is easily incorporated into existing workflows, enabling rapid and cost-effective research with consistent, accurate results for every scientist.

"As one of the foremost leaders of genome engineering, Jennifer will greatly enhance our efforts in bringing biology as a service to life sciences," said Paul Dabrowski, Chief Executive Officer of Synthego. "We are establishing the concept of, and setting the standards for, agile biopharma by bringing engineering principles to the field of biology. With Jennifer by our side, we will create a new approach to genome engineering. We are humbled and thrilled to bring her on board."